Recognizing that many of these researchers might not be experts in stem cell biology or might be working in laboratories with limited budgets and specialized equipment, Gameiro and Lin focused on making the organoid model easy to replicate. The goal was to provide a standardized, inexpensive platform that would allow scientists around the world to study how olfactory neurons regenerate and, perhaps more importantly, why that process fails in certain diseases.
By democratizing this technology, the Tufts team hopes to accelerate the pace of discovery across the field, moving from basic mouse biology to clinical applications for human health more rapidly.
Next Step: A Human Organoid
While the mouse model has provided invaluable insights, the ultimate objective for Lin and his colleagues is to translate these findings into human health. The team is currently working toward the development of a human olfactory organoid. Such a model would serve as a powerful platform for drug screening, allowing scientists to test potential treatments on living human tissue before moving to expensive and time-consuming clinical trials.
The use of organoids in pre-clinical research offers a "middle ground" that is often more effective than traditional animal models. Because organoids are derived from human cells, they can more accurately reflect human genetics and cellular responses. They have already been successfully developed for other organs, including the lungs and kidneys, but the human nose presents a unique set of challenges.
The primary hurdle lies in the difficulty of obtaining pure olfactory tissue. "It’s challenging to get pure olfactory tissue from humans," Lin explained. Currently, the process involves anesthetizing a patient and using a specialized brush—similar to the long swabs used in COVID-19 testing—to reach deep into the upper nasal cavity.
However, the sample collected is often a mixture of different cell types. Unlike the mouse model, where researchers can more easily isolate specific tissues, human samples typically contain a blend of respiratory stem cells and olfactory stem cells. These two types of cells look and behave differently, and for an organoid to be effective for studying smell, the olfactory cells must be isolated.
The research team’s next major challenge is to develop a simple, cost-effective technique for separating these human olfactory stem cells and "coaxing" them to grow and differentiate in a laboratory setting. If successful, this would open the door to personalized medicine for sensory disorders. A patient suffering from chronic smell loss could have their own cells harvested, grown into an organoid, and used to identify exactly which medications or therapies are most effective for their specific biological makeup.
As the team moves forward, the focus remains on the "dormant" cells that started it all. By proving that HBCs are vital partners in the regenerative process, the Tufts researchers have not only updated our understanding of nasal biology but have also identified a new potential target for therapies aimed at restoring one of our most essential connections to the world around us. Through international collaboration and a commitment to accessible science, the path toward treating sensory loss is becoming clearer, one cell at a time.
